Canis ISSN: 2398-2942

Dirlotapide

Synonym(s): Slentrol

Contributor(s): Alexander German

Introduction

Name

  • Dirlotapide.

Class of drug

  • Microsomal triglyceride transfer protein inhibitor.

Description

Chemical name

  • (S)-N-(2-[Benzyl(methyl)amino]-2-oxo-1-phenylethyl)-1-methyl-5-[4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamido]-1 H-indole-2-carboxamide.

Molecular formula

  • C40H33F3N4O3

Molecular weight

  • 674.73

Physical properties

  • Colorless to pale yellow oral solution.

Storage requirements

  • Store at room temperature 15-30°C (59-86°F).
  • Light sensitive.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Indicated for the management of obesity Obesity in dogs. To be used as part of an overall weight management program, which also includes appropriate dietary changes and exercise.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Monitor drug interactions closely.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references fromPubMed.
  • Wren J A, Ramudo AA, Campbell S L, King V L, Eagleson J S, Gossellin J & Sunderland S J (2007)Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America.J Vet Pharmacol Ther30Suppl 1, 81-89PubMed.
  • Gossellin J, McKelvie J, Sherington J, Wren J A, Eagleson J S, Rowan T G & Sunderland S J (2007)An evaluation of dirlotapide to reduce body weight of client-owned dogs in two placebo-controlled clinical studies in Europe.J Vet Pharmacol Ther30Suppl 1, 66-72PubMed.
  • Merritt D A, Bessire A J, Vaz A D, Sams J P & Lynch M P (2007)Absorption, distribution, metabolism, and excretion of dirlotapide in the dog.J Vet Pharmacol Ther30Suppl 1, 17-23PubMed.
  • Wren J A, Gossellin J, & Sunderland S J (2007)Dirlotapide: a review of its properties and role in the management of obesity in dogs.J Vet Pharmacol Ther30Suppl 1, 11-16 (Review)PubMed.

Other sources of information


ADDED